hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer

被引:21
作者
Ercoli, A
Ferrandina, G
Raspaglio, G
Marone, M
Maggiano, N
Del Mastro, P
Panici, PB
Mancuso, S
Scambia, G
机构
[1] Univ Cattolica Sacro Cuore, Dept Gynecol, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Pathol, I-00168 Rome, Italy
[3] Ist Ric Biol Mol, Pomezia, Italy
关键词
hMSH2; GTBP; ovarian cancer; cisplatin;
D O I
10.1038/sj.bjc.6690579
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Defects in DNA mismatch repair have been associated with both hereditary and sporadic forms of human cancer. Most of the attention has been focused on the incidence and genetics of mismatch repair defects, while little is known about the expression levels of the mismatch repair proteins and their significance in cancer cell biology. In this study, both the expression levels of hMSH2 and GTBP proteins were investigated by Western blotting in 20 untreated epithelial ovarian cancers. For these analyses, a commercial anti-hMSH2 monoclonal antibody and a newly generated mouse monoclonal anti-GTBP antibody were used, hMSH2 and GTBP proteins were detected by Western blotting in 19 out of 20 (95%) samples analysed and were found to be directly correlated (r= +0.51, P = 0.025). hMSH2 expression was significantly higher in ovarian cancer cells originating from solid tumours than from ascites (H = 4.5, P = 0.033), whereas GTBP content did not significantly differ according to the origin of cancer cells. No statistically significant differences were found in the distribution of hMSH2 and GTBP levels according to the age of the patients, grade of differentiation, histotype and extent of surgical debulking. The amount of hMSH2 protein was demonstrated to be significantly lower in stage IV than in stage III patients (H = 7.35, P = 0.007). Moreover, significantly lower hMSH2 levels were observed in non-responding patients compared to patients who achieved complete or partial response to cisplatin-based chemotherapy (H = 4.88, P = 0.027). Conversely, GTBP levels were not distributed differently according to stage of disease and chemotherapy response. Our study suggests a possible involvement of hMSH2 in ovarian cancer cell biology and susceptibility to chemotherapy. The possible biological and/or clinical role of GTBP expression in ovarian cancer patients remains to be elucidated.
引用
收藏
页码:1665 / 1671
页数:7
相关论文
共 26 条
[1]   hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6 [J].
Acharya, S ;
Wilson, T ;
Gradia, S ;
Kane, MF ;
Guerrette, S ;
Marsischky, GT ;
Kolodner, R ;
Fishel, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13629-13634
[2]  
Aebi S, 1996, CANCER RES, V56, P3087
[3]  
[Anonymous], 1979, HDB REP RES CANC TRE
[4]   Microsatellite instability differences between familial and sporadic ovarian cancers [J].
Arzimanoglou, II ;
Lallas, T ;
Osborne, M ;
Barber, H ;
Gilbert, F .
CARCINOGENESIS, 1996, 17 (09) :1799-1804
[5]  
BOYER JC, 1995, CANCER RES, V55, P6063
[6]  
BRANCH P, 1995, CANCER RES, V55, P2304
[7]   hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. [J].
Brown, R ;
Hirst, GL ;
Gallagher, WM ;
McIlwrath, AJ ;
Margison, GP ;
vanderZee, AGJ ;
Anthoney, DA .
ONCOGENE, 1997, 15 (01) :45-52
[8]   Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents [J].
Dosch, J ;
Christmann, M ;
Kaina, B .
CARCINOGENESIS, 1998, 19 (04) :567-573
[9]   Human MutS alpha recognizes damaged DNA base pairs containing O-6-methylguanine, O-4-methylthymine, or the cisplatin-d(GpG) adduct [J].
Duckett, DR ;
Drummond, JT ;
Murchie, AIH ;
Reardon, JT ;
Sancar, A ;
Lilley, DM ;
Modrich, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6443-6447
[10]  
Eshleman James R., 1995, Current Opinion in Oncology, V7, P83